[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020

October 2020 | 70 pages | ID: P22563AD7A7EEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020

SUMMARY

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Respiratory, Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Genetic Disorders, Metabolic Disorders and Undisclosed which include indications Arterial Thrombosis, Coronavirus Disease 2019 (COVID-19), Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Acute Respiratory Distress Syndrome, Alpha-1 Antitrypsin Deficiency (A1AD), Breast Cancer, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Melanoma, Metastatic Lung Cancer, Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Neurotoxicity Syndromes, Non-Small Cell Lung Cancer, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Pneumonia, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Unspecified and Venous (Vein) Thrombosis.
Furthermore, this report also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
Accendatech Au Pty Ltd
Beam Therapeutics Inc
Jazz Pharmaceuticals Plc
MDI Therapeutics Inc
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
defibrotide sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDI-2268 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDI-2517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5614 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
Featured News & Press Releases
May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting
Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Veno-Occlusive Disease
Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Defitelio (defibrotide sodium) at ASH 2019 Annual Meeting
Oct 10, 2019: Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical trial evaluating defibrotide for the prevention of CAR-T Associated Neurotoxicity
Sep 04, 2019: Launch of Defitelio injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease)
Jun 18, 2019: Marketing approval of Defitelio by MHLW for the treatment of sinusoidal obstruction syndrome / hepatic veno-occlusive disease
May 16, 2019: Jazz Pharmaceuticals to present new data on defitelio at upcoming EHA Congress
Mar 25, 2019: Experimental drug reverses high cholesterol, obesity-related nonalcoholic fatty liver disease in animals
Nov 28, 2018: Jazz Pharmaceuticals to present data on Defitelio at ASH 2018 Annual Meeting
Oct 17, 2018: New Drug Application Filed for defibrotide sodium
Sep 19, 2018: Nippon Shinyaku announces orphan drug designation granted to NS-73
Sep 19, 2018: Nippon Shinyaku: Orphan drug designation granted to NS-73
Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Accendatech Au Pty Ltd, H2 2020
Pipeline by Beam Therapeutics Inc, H2 2020
Pipeline by Jazz Pharmaceuticals Plc, H2 2020
Pipeline by MDI Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


More Publications